Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2385 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Grace Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Development Center Americas, Inc., Cambridge, MA, USA. Hauptthemen laut MEDLINE: Drug Interactions, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors, Rifampin. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Maribavir, an orally available antiviral agent, has been approved in multiple countries for the treatment of patients with refractory post‐transplant cytomegalovirus (CMV) infection and/or disease. Maribavir is primarily metabolized by CYP3A4; coadministration with CYP3A4 inducers and inhibitors may significantly alter maribavir exposure, thereby affecting its efficacy and safety. The effect of CYP3A4 inducers and inhibitors on maribavir exposure was evaluated based on a drug‐drug interaction (DDI) study and physiologically‐based pharmacokinetic (PBPK) modeling. The effect of rifampin (a strong inducer of CYP3A4 and moderate inducer of CYP1A2), administered at a 600 mg dose once daily, on maribavir pharmacokinetics was assessed in a clinical phase 1 DDI study in healthy participants. A full PBPK model for maribavir was developed and verified using in vitro and clinical pharmacokinetic data from phase 1 studies. The verified PBPK model was then used to simulate maribavir DDI interactions with various CYP3A4 inducers and inhibitors. The DDI study results showed that coadministration with rifampin decreased the maribavir maximum plasma concentration (C max ), area under the plasma concentration‐time curve (AUC), and trough concentration (C trough ) by 39%, 60%, and 82%, respectively. Based on the results from the clinical DDI study, the coadministration of maribavir with rifampin is not recommended. The PBPK model did not predict a clinically significant effect of CYP3A4 inhibitors on maribavir exposure; however, it predicted that strong or moderate CYP3A4 inducers, including carbamazepine, efavirenz, phenobarbital, and phenytoin, may reduce maribavir exposure to a clinically significant extent, and may prompt the consideration of a maribavir dosing increase, in accordance with local approved labels and/or regulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Takeda Development Center Americas, Inc., Cambridge, MA, USA.
- Certara UK Ltd., Simcyp Division, Sheffield, UK.
ORCID-Profile: Grace Chen, Kefeng Sun, Ingrid Michon, Sibylle Neuhoff, Katarina Ilic, Ivy H Song
Zitieren
APA
Chen, G., Sun, K., Michon, I., Barter, Z., Neuhoff, S., Ghosh, L., Ilic, K., & Song, I. H. (2024). Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2385
Vancouver
Chen G, Sun K, Michon I, Barter Z, Neuhoff S, Ghosh L, et al. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2385
BibTeX
@article{Chen2024,
author = {Chen, Grace and Sun, Kefeng and Michon, Ingrid and Barter, Zoe and Neuhoff, Sibylle and Ghosh, Lipika and Ilic, Katarina and Song, Ivy H},
title = {Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug‐Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2385}
}
EUVIMED